Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has signed a Letter of Intent with anti-aging, health and wellness company, Doctors Optimal Formula LLC, to create Retinalyze, LLC, an equally owned joint venture, to develop the first SVM-based retinal image analysis for retinal disease assessment and treatment protocols. Designed to assist physicians, the first product "Retinalyze Analytics Software" will use state-of-the-art mathematical algorithms and image-based pattern recognition technology to capture and analyze eye diseases such as age-related macular degeneration (AMD), the leading cause of blindness in adults 55 years and older. “With Health Discovery’s SVM technology having been successfully applied to digital pathology and radiology in various applications, we are excited to develop Retinalize Analytics, with the expertise provided by the Doctors Optimal Formula’s Ophthalmology experts, to be able to address the needs of the potentially billion people throughout the world with life altering retinal diseases such as macular degeneration,” explains Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. AMD Alliance International reports the worldwide cost of visual impairment due to AMD alone at $343 billion, including $255 billion in direct health care costs. In North America alone, the associated health costs of AMD is near $98 billion. Even more importantly, these costs are set to rise dramatically through 2020 unless effective prevention and treatment strategies are adopted worldwide. “Retinalyze Analytics will help physicians better "see" retina associated diseases, thereby providing a more accurate diagnostic interpretation of the images analyzed. With more than 400,000 optometrists, ophthalmologists and primary care providers testing and diagnosing such diseases in the U.S. alone, Retinalyze Analytics has the potential to become THE industry-changing standard for retinal testing,” explains Howard Loff, M.D., a leading oculoplastic surgeon and CEO and founder of Doctors Optimal Formula LLC. “We have great confidence that the SVM technology guided by HDC's expertise can successfully assist physicians with improvement in the interpretation of retinal images that are currently part of standard ophthalmologic exams. Beginning at age 40, it is recommended that all adults be screened for eye disease every two years unless there are indications requiring more frequent screening. Additionally, our proprietary technology will store images and assist in the early detection of any changes thereby optimizing a physician's diagnosis allowing early treatment to prevent vision loss, blindness, disability and premature death.”
Along with Dr. Loff, Sunil Malkani, M.D., a leading vitreo-retinal surgeon and founder of Malkani Retina Center in Fort Myers, FL, will oversee the development of Retinalyze Analytics to ensure optimal clinical benefits. Using Doctors Optimal Formula's current Provider database of more than 10,000 physicians, the integration of Retinalyze Analytics into physician practices is expected to be readily marketable.In addition to AMD, Retinalyze Analytics is slated to assist in the detection of various retinal disorders, including retinal lesions and vascular diseases that include diabetic retinopathy, hypertensive retinopathy and ocular melanoma. “Early diagnosis and treatment is critical with retinal diseases, enabling patients to be treated prior to becoming symptomatic, which can significantly improve the patients prognosis. Retinalyze Analytics will provide the most advanced SVM-based interpretations to help physicians analyze these diseases and tumors, potentially months if not years sooner than previously possible,” adds Dr. Malkani. Physicians interested in learning about Retinalyze Analytics’ referral and reimbursement program may contact Howard Loff, MD at Hloffmd@doctorsoptimalformula.com. About Doctors Optimal Formula LLC Having been founded by medical doctors, Doctors Optimal Formula prides itself on providing the best, scientifically formulated nutritional supplements and anti-aging skin care available today! Focusing on maintaining and improving the health and well being of our customers, Doctors Optimal Formula has become vertically integrated to encompass all aspects of healthcare, such as Vision Care Plans, Prescription Pharmacy Plans and a physician provider network of over 10,000 physicians. For more information, visit www.DoctorsOptimalFormula.com. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.